Released May 9, 2022, before the open
10-Q filed May 9, 2022, 39 days after period end · 0000950170-22-008244
Q1 2022 · 10-Q
Revenue—
Net Income-$7.16M-$7.16M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.07-$0.07 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$7,182,000N/M
Operating Cash Flow-$7,942,000N/M
Free Cash Flowderived-$8,136,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Net Income | -$7.16M | -$7.42M | -$6.40M | -$10.77M |
| EPS Diluted | -$0.07 | -$0.14 | -$0.90 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR